Clinical responses to ERK inhibition in BRAF(V600E)-mutant colorectal cancer predicted using a computational model

Approximately 10% of colorectal cancers harbor BRAF (V600E) mutations, which constitutively activate the MAPK signaling pathway. We sought to determine whether ERK inhibitor (GDC-0994)-containing regimens may be of clinical benefit to these patients based on data from in vitro (cell line) and in viv...

Descripción completa

Detalles Bibliográficos
Autores principales: Kirouac, Daniel C., Schaefer, Gabriele, Chan, Jocelyn, Merchant, Mark, Orr, Christine, Huang, Shih-Min A., Moffat, John, Liu, Lichuan, Gadkar, Kapil, Ramanujan, Saroja
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5460205/
https://www.ncbi.nlm.nih.gov/pubmed/28649441
http://dx.doi.org/10.1038/s41540-017-0016-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5460205/
https://www.ncbi.nlm.nih.gov/pubmed/28649441
http://dx.doi.org/10.1038/s41540-017-0016-1

Ejemplares similares